Drug ID:Drug3
Drug Name:Ethanol
CID:702
DrugBank ID:DB00898
Modality:Small Molecule
Groups:approved
US Approved:YES
Other Approved:YES
Identifier: NCT03042091
Molecular Formula:C2H6O
Molecular Weight:46.07 g/mol
Isomeric SMILES:CCO
Synonyms:ethanol; ethyl alcohol; alcohol; 64-17-5; grain alcohol; Methylcarbinol; Ethyl hydrate; Tecsol; Algrain; Anhydrol
Phase 0: 27
Phase 1: 72
Phase 2: 55
Phase 3: 29
Phase 4: 49
Description:A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in alcoholic beverages. [PubChem]

Molecular Structure

2D Molecular Structure

Knowledge Graph

dtIDCIDCompound NameGene IDGene NameSpeciesPubMed IDsAction
dt12 702 Ethanol 57498 KIDINS220 Mus musculus (house mouse) 30319688 Ethanol affects the splicing of KIDINS220 mrna|ethanol results in increased expression of KIDINS220 mRNA
dt13 702 Ethanol 63971 KIF13A Mus musculus (house mouse) 30319688 Ethanol results in increased expression of KIF13A mrna|ethanol affects the splicing of KIF13A mRNA
dt14 702 Ethanol 23303 KIF13B Mus musculus (house mouse) 30319688 Ethanol results in increased expression of KIF13B mRNA
dt15 702 Ethanol 81930 KIF18A Mus musculus (house mouse) 30517762 [carbon tetrachloride co-treated with ethanol] results in increased expression of KIF18A mRNA
dt16 702 Ethanol 547 KIF1A Mus musculus (house mouse) 30319688 Ethanol results in increased expression of KIF1A mrna|ethanol affects the splicing of KIF1A mRNA
dt17 702 Ethanol 547 KIF1A Mus musculus (house mouse) 29018328 Ethanol results in decreased expression of KIF1A mRNA
dt18 702 Ethanol 566766 kif1ab Danio rerio (zebrafish) 29361514 Ethanol results in increased expression of KIF1AB mRNA
dt19 702 Ethanol 23095 KIF1B Mus musculus (house mouse) 30319688 Ethanol results in increased expression of KIF1B mrna|ethanol affects the expression of and affects the splicing of KIF1B mRNA
dt20 702 Ethanol 10749 KIF1C Mus musculus (house mouse) 30319688 Ethanol results in increased expression of KIF1C mRNA
dt21 702 Ethanol 55605 KIF21A Mus musculus (house mouse) 30319688 Ethanol affects the splicing of KIF21A mRNA

  • No data available

Phase Distribution
Phase Description
  • Phase 0: Exploratory trials to assess drug behavior in humans
  • Phase 1: Safety trials to determine safe dosage range
  • Phase 2: Efficacy trials to evaluate therapeutic effects
  • Phase 3: Large-scale trials to confirm efficacy and safety
  • Phase 4: Post-marketing surveillance for long-term safety and efficacy

Trial IDTitlePhaseStatusSponsorIndicationsInterventions
NCT01705522 Multimodal Approach in IBD Patients None UNKNOWN Clinical Hospital Colentina Ulcerative Colitis|Crohn's Disease|Nonalcoholic F… None Details
NCT06814600 Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients None RECRUITING Centre Hospitalier Universitaire Saint Pierre NAFLD|Inflammatory Bowel Diseases|Steatosis|Fibro… DIAGNOSTIC_TEST: Transient elastometry Details
NCT04014413 Safety and Efficacy of Fecal Microbiota Transplantation None RECRUITING Chinese University of Hong Kong Crohn Disease|Ulcerative Colitis|Celiac Disease|I… PROCEDURE: Fecal Microbiota Transplantation Details
NCT01476995 Prognostic Indicators as Provided by the EPIC ClearView None COMPLETED Epic Research & Diagnostics, Inc. Coronary Artery Disease|Congestive Heart Failure|… None Details
ACTRN12622000579796 A single dose, randomised, 2-period, 2-sequence, crossover, relative bioavailability study comparing 2 x 10 mg R-178 tablets with 2 x 10 mg 2-amino-1,7-dihydro-6H-purine-6-thione tablets administered orally in healthy participants under fasting conditions. PHASE1 None Zenith Technology Corporation Limited 2-amino-1,7-dihydro-6H-purine-6-thione is indicat… Single dose, crossover study design whereby each … Details
JPRN-UMIN000045216 Development of intestinal environment evaluation system by integrated analysis of intestinal microbiota research database - Development of intestinal environment evaluation system by integrated analysis of intestinal microbiota research database Not Available Recruiting Department for Medical Innovation and Translational Medical Science, Kyoto Prefectural University of Medicine healthy individuals without diseases, inflammator… None Details
IRCT20150304021342N2 The effects of dietary modification programme (low-fat, low-carb and high-protein diet) on mood status, fatigue and quality of life in patients with ulcerative colitis Not Available Not Recruiting Esfahan University of Medical Sciences Ulcerative colitis. Ulcerative colitis Intervention 1: Intervention group: Patients who … Details
NCT04328259 Prevalance of non_ Alcoholic Fatty Liver Diseases in Patient With Inflammatory Bowel Diseases Attending Assiut University Hospitals Not Available Not recruiting Assiut University Inflammatory Bowel Disease Patients None Details
NCT04306939 Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study Not Available Not recruiting University of Pittsburgh Chronic Pancreatitis;Inflammatory Bowel Diseases;… Other: venipuncture;Behavioral: Questionnaires;Ot… Details
ACTRN12618000122257 The effects of a multidisciplinary Gastroenterology and Hepatology Integrated Care Clinic approach in patients with chronic gastrointestinal disorders: a randomised controlled trial. Not Available Recruiting Princess Alexandra Hospital Nonalcoholic Fatty Liver Disease;Nonalcoholic Ste… The Department of Gastroenterology and Hepatology… Details
JPRN-UMIN000019486 Enterobacterial analysis for the precise medical care (precision medicine) for diabetes, non-alcoholic lipid liver disease / non-alcoholicity fat hepatitis, inflammatory bowel disease, and irritable bowel syndrome. - Enterobacterial analysis for the precise medical care (precision medicine). Not Available Recruiting Kyoto Prefectural University of Medicine diabetes, non-alcoholic lipid liver disease / non… None Details
DRKS00004935 Attitudes towards eCommunication_in treatment of chronically ill patients _ - EC@T Not Available Recruiting Uniklinikum Freiburg, Institut f Qualitsmanagement und Sozialmedizin Chronic back pain_Chronic ischemic heart disease_… Group 1: The EC@T-project consists of three subst… Details
NCT01793168 Coordination of Rare Diseases at Sanford Not Available Recruiting Sanford Health Rare Disorders;Undiagnosed Disorders;Disorders of… None Details
ACTRN12609000913279 Does cognitive-behavioural therapy (CBT) improve outcomes in inflammatory bowel disease (IBD)? A pilot randomised controlled trial Not Available Not Recruiting Royal Adelaide Hospital Inflammatory bowel disease (IBD); Inflammatory b… Preliminary screening of interested subjects will… Details

Disease IDDisease NameDefinitionCategoryRelated DrugsMechanism
No data available

Strategy IDTherapeutic StrategySynonymsRelated DrugsMechanism
No data available

Preventive Effects of an UPLC-DAD-MS/MS Fingerprinted Hydroalcoholic Extract of…

PMID: 29727864
Year: 2018
Relationship Type: Treatment Score: 5.3

Although traditionally used to improve indigestion, diarrhea, dysentery, and constipation, the therapeutic effects of Citrus aurantium on intestinal …

Micro-RNA-155 deficiency prevents alcohol-induced serum endotoxin increase and …

PMID: 25156614
Year: 2014
Relationship Type: Association Score: 5.3

BACKGROUND: Chronic alcohol impairs gut barrier function and induces inflammatory cytokines. The effects of acute alcohol binge on the gut are partia…

Showing 61-62 of 62 articles